Corporate Presentation
March 2015
Narvitas Medical Devices
• Develop, patent, manufacture and sell propriety medical
devices
• 3 Initial Platforms, each lev...
Management Team
Glenn Foley Co-Founder & Director
Chief Executive Officer
AVE, Medtronic, Precision Vascular
Arthur Malvet...
Clinical Challenge New Modality Improved
Standard of Care
• Challenge: GYN Laparoscopic Surgery Access
– Veress Needle is ...
Product Development
RFQ’s out to the following engineering design firms:
• Movement ( Dublin ) LapDome Mini
• Advant ( Gal...
Intellectual Property Update
Original claims in “temporary pneumoperitoneum” ( Foley 1 )
• Owned by Medical Device Interna...
New Strategic Partners
Velocimed St. Jude Veryan BioSensors ( distribution )
Bridgepoint BSC
Lutomix Bard
MedNova Abbott
H...
Product Pipeline and Timing
Device Class CE FDA JMOH
I CQ2 2015 CQ4 2015 CQI 2016
2A Kits inc Veress CQ1 2016 CQ2 2016 CQ4...
Distributor Strategy - USA
Surgical Principals Inc. Active Medical
EA Medical Mediflex
CS Surgical Adler Instruments
Suppo...
Financial Forecast
Liquidity and Exit
What we are looking for?
€452k
Subscribed
€550k
Open
€2.3m
Valuation
of 12

Narvitas PPT Presentation April 2015

Corporate Presentation
Published on: Mar 3, 2016
Published in: Health & Medicine      
Source: www.slideshare.net


Transcripts - Narvitas PPT Presentation April 2015

  • 1. Corporate Presentation March 2015
  • 2. Narvitas Medical Devices • Develop, patent, manufacture and sell propriety medical devices • 3 Initial Platforms, each leveraging the core technology • Class 1 - Large market segment – High Volume procedures Laparoscopic Epidural Anesthesia Med Surg 8.1 mil procedures worldwide 130 mil birth 60% epidurals In dwelling catheter collection EpiDome Jaws
  • 3. Management Team Glenn Foley Co-Founder & Director Chief Executive Officer AVE, Medtronic, Precision Vascular Arthur Malvett Co-Founder & Director Chief Operating Officer Life Care Medical, Midland Bank Daragh Sharkey Co-Founder & Director Sales & Business Development Aerogen, Altana, Trojan Med
  • 4. Clinical Challenge New Modality Improved Standard of Care • Challenge: GYN Laparoscopic Surgery Access – Veress Needle is a blind shot – Labor intensive • 10-12 minutes to full insulflation – Published complication rates = 2-4% • Vital organs in abdominal bed • Revert to open surgery • One week hospitalization • New Modality
  • 5. Product Development RFQ’s out to the following engineering design firms: • Movement ( Dublin ) LapDome Mini • Advant ( Galway ) LapDome Plus • Knowvention ( US ) EpiDome • Devicix ( US ) “Jaws” • Design LapDome Pedi • Narvitas access to engineering firms • Narvitas access to University of Minnesota Medical Center MDs
  • 6. Intellectual Property Update Original claims in “temporary pneumoperitoneum” ( Foley 1 ) • Owned by Medical Device International and assigned to Life Care Medical • Life Care defaulted • Default judgment in favor of Medical Device International in Hong Kong • Sealed judgment awarded to Medical Device International • Medical Device International assigned property to Narvitas Second set of claims around “temporary pneumoperitoneum” ( Foley 2 ) • Filed in UK • Search report uneventful • Move to PCT EpiDome claims • UK search report yielded inventive steps • Move to PCT
  • 7. New Strategic Partners Velocimed St. Jude Veryan BioSensors ( distribution ) Bridgepoint BSC Lutomix Bard MedNova Abbott High Growth Technology Group Narvitas UK branch office
  • 8. Product Pipeline and Timing Device Class CE FDA JMOH I CQ2 2015 CQ4 2015 CQI 2016 2A Kits inc Veress CQ1 2016 CQ2 2016 CQ4 2016 CQ4 2015 CQ4 2015 CQ1 2016 CQ1 2016 CQ2 2016 CQ2 2016
  • 9. Distributor Strategy - USA Surgical Principals Inc. Active Medical EA Medical Mediflex CS Surgical Adler Instruments Support Programs from Eisner Medical Ltd • Europe/ME referral centers • White papers • Registry • Published papers • Economic Impact analysis Eisner Medical Ltd– Consultants who are advising on market entry
  • 10. Financial Forecast
  • 11. Liquidity and Exit
  • 12. What we are looking for? €452k Subscribed €550k Open €2.3m Valuation

Related Documents